Xeris Biopharma (XERS) News Today $4.78 -0.05 (-1.04%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.80 +0.02 (+0.52%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XERS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Millennium Management LLC increased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 34.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,948,552 shares of the company's stock after acquMay 29 at 3:38 AM | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)BNP Paribas Financial Markets bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 100,012 shares of the company's stock, valued at approximately $339,000. BNPMay 28 at 3:16 AM | marketbeat.comXeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street ZenWall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday.May 24, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Downgraded to "Hold" Rating by Wall Street ZenMay 23, 2025 | americanbankingnews.comXeris Announces Details for Analyst & Investor DayMay 20, 2025 | businesswire.comStonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Stonepine Capital Management LLC bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 182,317 shares of the company's stock, valued at apMay 20, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. grew its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 38.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,363,452 shares of the company's stock after buying an adMay 20, 2025 | marketbeat.comLeerink Partnrs Weighs in on Xeris Biopharma Q2 EarningsXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Monday, May 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will earn ($0.01)May 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Parkman Healthcare Partners LLC raised its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 465.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 578,511 shares of the company's stockMay 16, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Lowers Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Schonfeld Strategic Advisors LLC reduced its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 40.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,000 shares of thMay 13, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comDriehaus Capital Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Driehaus Capital Management LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 594,015 shares of the company's stock, valuedMay 12, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comXeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 9, 2025 | finance.yahoo.comTudor Investment Corp ET AL Reduces Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Tudor Investment Corp ET AL cut its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 39.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 305,186 shares of the company's stock after selling 202,171 shares during thMay 9, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comXeris Biopharma Reports Record First Quarter 2025 Financial ResultsMay 8, 2025 | businesswire.com4XERS : Earnings Outlook For Xeris Biopharma HoldingsMay 7, 2025 | benzinga.comXeris Biopharma Holdings: Looking For More Growth In Q1 EarningsMay 7, 2025 | seekingalpha.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Reduced by Caxton CorpCaxton Corp cut its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 60.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,015,157 shares of the company's stock aftMay 7, 2025 | marketbeat.comXeris Biopharma (XERS) Projected to Post Earnings on ThursdayXeris Biopharma (NASDAQ:XERS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-xeris-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comXeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase - Time to Buy?Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - What's Next?April 30, 2025 | marketbeat.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To ProfitApril 26, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 23, 2025 | msn.comJPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)JPMorgan Chase & Co. increased its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 166.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,043,441 shares of tApril 22, 2025 | marketbeat.comRenaissance Technologies LLC Raises Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Renaissance Technologies LLC grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 31.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,098,840 shares of the company's stock after buying an additional 500,120 shares duringApril 21, 2025 | marketbeat.comEAM Investors LLC Buys New Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)EAM Investors LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 222,377 shares of the company's stock, valApril 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 4.9% - Here's What HappenedXeris Biopharma (NASDAQ:XERS) Stock Price Down 4.9% - Time to Sell?April 18, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short InterestXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 17,040,000 shares, an increase of 52.0% from the March 15th total of 11,210,000 shares. Based on an average daily trading volume, of 2,810,000 shares, the days-to-cover ratio is currently 6.1 days. Currently, 12.0% of the shares of the stock are sold short.April 18, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Shares Up 4.9% - What's Next?Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% - Here's What HappenedApril 17, 2025 | marketbeat.comKennedy Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Kennedy Capital Management LLC boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 666,095 shares of theApril 16, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. increased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,899,063 shares of the company's stock after purchasing an additional 1April 16, 2025 | marketbeat.comCenterBook Partners LP Sells 2,791,929 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)CenterBook Partners LP reduced its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 80.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 690,077 shares of the company's stock after selling 2,791,929 shares during the period. CenterBookApril 12, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's WhyXeris Biopharma (NASDAQ:XERS) Shares Down 6.2% - Should You Sell?April 3, 2025 | marketbeat.comAIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)AIGH Capital Management LLC raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,574,846 shares of the company's stock aftMarch 31, 2025 | marketbeat.comXeris Announces Changes to Its Board of DirectorsMarch 28, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comXeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - Time to Buy?March 25, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 106.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,332 shares ofMarch 23, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 SharesXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 22, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's WhyXeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's What HappenedMarch 22, 2025 | marketbeat.com12 Best Stocks to Invest in for a Stock Market GameMarch 20, 2025 | insidermonkey.comXeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market GameMarch 19, 2025 | insidermonkey.comCalculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)March 18, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Sets New 12-Month High - Still a Buy?Xeris Biopharma (NASDAQ:XERS) Hits New 52-Week High - Here's What HappenedMarch 18, 2025 | marketbeat.comFDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aidMarch 17, 2025 | markets.businessinsider.comXeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic AidMarch 17, 2025 | finance.yahoo.comGlobeflex Capital L P Takes $424,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Globeflex Capital L P purchased a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 125,210 shares of the company's stockMarch 17, 2025 | marketbeat.comXeris Biopharma: Low Risk, Low Excitement Solid Revenue GeneratorMarch 16, 2025 | seekingalpha.com Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Media Mentions By Week XERS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XERS News Sentiment▼0.950.87▲Average Medical News Sentiment XERS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XERS Articles This Week▼52▲XERS Articles Average Week Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CPRX News MTSR News MOR News SRRK News PTGX News CRNX News MLTX News IMVT News HCM News AAPG News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XERS) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XERS Stock Free XERS Stock Alerts